Van Breusegem Paulien, Verswijvel Geert, Fransis Sabine, Van der Speeten Kurt
Department of Surgical Oncology, Hospital Oost-Limburg, Schiepse Bos 6, 3600 Genk, Belgium.
Department of Radiology, Hospital Oost-Limburg, Genk, Belgium.
Indian J Surg Oncol. 2023 Jun;14(Suppl 1):109-121. doi: 10.1007/s13193-022-01679-4. Epub 2022 Dec 17.
Urachal carcinoma (UC) is a rare and aggressive tumor arising from the urachal remnants, with the potential for peritoneal dissemination. Patients diagnosed with UC often have a poor prognosis. To date, there is no standardized treatment. Our objective is to present two cases of patients with peritoneal carcinomatosis (PC) secondary to an UC, who were treated with cytoreductive surgery (CRS) and hyperthermic peroperative intraperitoneal chemotherapy (HIPEC). A review of the literature on CRS and HIPEC in UC suggests CRS and HIPEC to be a safe and viable treatment option. Two patients with PC of UC underwent CRS and HIPEC in our institution. All available data were gathered and reported on. A literary search was carried out to find all available cases of patients with PC secondary to UC treated with CRS and HIPEC. Both patients underwent CRS and HIPEC and are currently free of recurrence. Literature research revealed nine other publications adding up to a total of 68 additional cases. CRS and HIPEC can provide satisfactory long-term oncological outcome with acceptable morbidity and mortality rates in patients with PC of urachal origin. It should be considered as a safe and feasible treatment option with curative potential.
脐尿管癌(UC)是一种起源于脐尿管残余组织的罕见且侵袭性肿瘤,具有腹膜播散的可能性。诊断为UC的患者预后通常较差。迄今为止,尚无标准化治疗方法。我们的目的是介绍两例继发于UC的腹膜癌(PC)患者,他们接受了减瘤手术(CRS)和术中腹腔内热灌注化疗(HIPEC)。对UC中CRS和HIPEC的文献综述表明,CRS和HIPEC是一种安全可行的治疗选择。我们机构有两名UC合并PC的患者接受了CRS和HIPEC。收集并报告了所有可用数据。进行了文献检索,以查找所有接受CRS和HIPEC治疗的继发于UC的PC患者的可用病例。两名患者均接受了CRS和HIPEC,目前无复发。文献研究发现了其他九篇出版物,共计68例额外病例。对于脐尿管起源的PC患者,CRS和HIPEC可以提供令人满意的长期肿瘤学结果,发病率和死亡率可接受。它应被视为一种具有治愈潜力的安全可行的治疗选择。